Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Clinical translation of ferumoxytol-based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population.

Autor: Fredrickson J; Clinical Imaging Group, Genentech, Inc., South San Francisco, California, USA.; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA., Serkova NJ; Department of Anesthesiology, University of Colorado Cancer Center, Aurora, Colorado, USA., Wyatt SK; Department of Biomedical Imaging, Genentech, Inc., South San Francisco, California, USA., Carano RA; Department of Biomedical Imaging, Genentech, Inc., South San Francisco, California, USA., Pirzkall A; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA., Rhee I; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA., Rosen LS; Department of Medicine, Division of Hematology and Oncology, UCLA, Santa Monica, California, USA., Bessudo A; San Diego Pacific Oncology Hematology Associates Inc., Encinitas, California, USA., Weekes C; Department of Medical Oncology, University of Colorado Cancer Center, Aurora, Colorado, USA., de Crespigny A; Clinical Imaging Group, Genentech, Inc., South San Francisco, California, USA.; Oncology Clinical Development, Genentech, Inc., South San Francisco, California, USA.

Publikováno v: Magnetic resonance in medicine [Magn Reson Med] 2017 Feb; Vol. 77 (2), pp. 814-825. Date of Electronic Publication: 2016 Feb 26.

Brain Distribution and Efficacy of the Brain Penetrant PI3K Inhibitor GDC-0084 in Orthotopic Mouse Models of Human Glioblastoma.

Autor: Salphati L; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California salphati.laurent@gene.com., Alicke B; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Heffron TP; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Shahidi-Latham S; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Nishimura M; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Cao T; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Carano RA; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Cheong J; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Greve J; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Koeppen H; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Lau S; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Lee LB; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Nannini-Pepe M; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Pang J; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Plise EG; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Quiason C; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Rangell L; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Zhang X; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Gould SE; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Phillips HS; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California., Olivero AG; Departments of Drug Metabolism and Pharmacokinetics (L.S., S.S.-L., J.C., J.P., E.G.P., C.Q., X.Z.), Discovery Chemistry (T.P.H., A.G.O.), Cancer Signaling and Translational Oncology (B.A., M.N., M.N.-P., L.B.L., S.E.G., H.S.P.), Biomedical Imaging (T.C., R.A.C., J.G.), and Pathology (H.K., S.L., L.R.), Genentech Inc., South San Francisco, California.

Publikováno v: Drug metabolism and disposition: the biological fate of chemicals [Drug Metab Dispos] 2016 Dec; Vol. 44 (12), pp. 1881-1889. Date of Electronic Publication: 2016 Sep 16.

Preclinical Safety Profile of a Depleting Antibody against CRTh2 for Asthma: Well Tolerated Despite Unexpected CRTh2 Expression on Vascular Pericytes in the Central Nervous System and Gastric Mucosa.

Autor: Rajapaksa KS; Departments of Safety Assessment., Huang T; Immunology., Sharma N; Pathology., Liu S; Departments of Safety Assessment., Solon M; Pathology., Reyes A; Preclinical and Translational Pharmacokinetics., Paul S; Pathology., Yee A; Antibody Engineering., Tao J; Pathology., Chalasani S; Pathology., Bien-Ly N; Neuroscience., Barck K; Biomedical Imaging., Carano RA; Biomedical Imaging., Wang J; Biochemical and Cellular Pharmacology;, Rangell L; Pathology., Bremer M; OMNI Biomarker Development, Genentech Inc, South San Francisco, California, 94080., Danilenko DM; Departments of Safety Assessment., Katavolos P; Departments of Safety Assessment., Hotzel I; Antibody Engineering., Reif K; Immunology Preclinical and Translational Pharmacokinetics., Austin CD; Pathology caustin@gene.com.

Publikováno v: Toxicological sciences : an official journal of the Society of Toxicology [Toxicol Sci] 2016 Jul; Vol. 152 (1), pp. 72-84. Date of Electronic Publication: 2016 Apr 21.

Metabolic response of prostate cancer to nicotinamide phophoribosyltransferase inhibition in a hyperpolarized MR/PET compatible bioreactor.

Autor: Keshari KR; Department of Radiology, Memorial Sloan-Kettering Cancer Center (MSKCC), New York.; Molecular Pharmacology and Chemistry Program, Memorial Sloan-Kettering Cancer Center (MSKCC), New York., Wilson DM; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California., Van Criekinge M; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California., Sriram R; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California., Koelsch BL; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California., Wang ZJ; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California., VanBrocklin HF; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California., Peehl DM; Department of Urology, Stanford University, Stanford, California., O'Brien T; Department of Translational Oncology, Genentech Inc., South San Francisco, California., Sampath D; Department of Translational Oncology, Genentech Inc., South San Francisco, California., Carano RA; Department of Biomedical Imaging, Genentech Inc., South San Francisco, California., Kurhanewicz J; Department of Radiology and Biomedical Imaging, University of California, San Francisco, California.

Publikováno v: The Prostate [Prostate] 2015 Oct; Vol. 75 (14), pp. 1601-9. Date of Electronic Publication: 2015 Jul 14.